Aggressive & visceral disease
RIGHT Choice: Significant mPFS benefit with KISQALI vs combo CT in patients with aggressive disease. *(1)
9-month increase in mPFS with KISQALI vs combo CT. †(1)
* Aggressive disease features included symptomatic visceral metastases, rapid disease progression or impending visceral compromise, or markedly symptomatic non-visceral disease. (1)
†HR 0.61; 95% CI: 0.43–0.87, p=0.003. (1)
RIGHT Choice study design
Ribociclib Molecule
RIGHT Choice: N=222, is an open-label, multicentre, randomised phase 2 trial, in pre/perimenopausal women with clinically aggressive HR+/HER2− ABC (including symptomatic visceral metastases, rapid disease progression or impending visceral compromise or markedly symptomatic non-visceral disease) who were randomised 1:1 to first-line KISQALI (600 mg daily; 3 weeks on, 1 week off) plus letrozole/anastrozole and goserelin or investigator’s choice of combination CT (docetaxel plus capecitabine, paclitaxel plus gemcitabine, or capecitabine plus vinorelbine). The primary endpoint was PFS and secondary endpoints included TTF, 3-month TFR, ORR, CBR, TTR, OS, HRQOL and safety. (1)
KISQALI matches the tumour response rates seen with combo CT. (1)
KISQALI + AI + goserelin tumor response rates were consistent with combination chemotherapy. (1)
* Patients with complete or partial response without confirmation. (1)
† Patients with complete or partial response without confirmation (or stable disease lasting 24 weeks or more or noncomplete response without progressive disease lasting 24 weeks or more). (1)